What Current Reports Say About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Risk Assessment

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Current reports from medical literature and patient cases are shedding light on this potential association. Building on decades of health education that emphasizes informed patient-provider communication, this page summarizes what the research says and what it means for your care.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Among the adverse effects associated with its use, gastrointestinal complications are prominent and have raised concerns about a potential link to gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. This narrative examines the clinical presentation of gastroparesis, the pharmacology of Ozempic, reported adverse effects, mechanistic pathways, and risk considerations for affected patients in North Carolina, including settlement-related factors and the statute of limitations. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, weight loss, and impaired quality of life. In the context of Ozempic, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which may contribute to the development or exacerbation of gastroparesis.

Mechanistic Pathways and Risk Considerations

The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, a physiological effect that can become pathological in susceptible individuals. Prolonged use may lead to sustained delay in gastric emptying, mimicking the clinical picture of gastroparesis. While the prescribing information does not explicitly list gastroparesis as an adverse reaction, the high rates of nausea, vomiting, and dyspepsia suggest a potential for gastric motility disturbances. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have also been reported with Ozempic and other GLP-1 receptor agonists, but these are distinct from gastrointestinal effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Risk considerations for affected patients in North Carolina center on the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information highlights gastrointestinal adverse reactions but does not specifically warn of gastroparesis. Patients who developed gastroparesis after using Ozempic may argue that the manufacturer failed to provide adequate warnings about this risk. Settlement-related considerations include the need to establish a causal link between Ozempic use and the development of gastroparesis, which requires medical evidence such as temporal association, exclusion of other causes, and objective diagnostic testing. The timeline between exposure and documented harm is critical; symptoms often emerge during dose escalation or after prolonged use, and a clear chronology strengthens a claim.

Statute of Limitations in North Carolina for Ozempic-Related Gastroparesis Claims

In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury is discovered or should have been discovered. For gastroparesis, this means the clock starts when the patient becomes aware of the condition and its potential link to Ozempic. Given that gastrointestinal symptoms may be initially attributed to other causes, patients should seek prompt medical evaluation and document the onset of symptoms relative to Ozempic use. Legal counsel can provide guidance on filing deadlines and evidence requirements. In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which may contribute to gastroparesis. The mechanistic basis involves GLP-1 receptor-mediated slowing of gastric emptying. Patients in North Carolina who develop gastroparesis after using Ozempic should consider the adequacy of warnings, the timeline of exposure and harm, and the three-year statute of limitations for potential claims. Medical documentation and expert testimony are essential to establish causation and support settlement negotiations. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

What evidence is needed to establish a causal link between Ozempic and gastroparesis?

To establish a causal link, medical evidence such as a temporal association between Ozempic use and symptom onset, exclusion of other causes, and objective diagnostic testing (e.g., gastric emptying scintigraphy) is required. A clear chronology of exposure and documented harm strengthens a claim. Expert testimony may also be necessary to support causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.